Experimental drug combo aims to fight deadly brainstem glioma

NCT ID NCT02887040

Not yet recruiting Disease control Sponsor: Burzynski Research Institute Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This phase 3 trial tests whether adding two experimental drugs (Atengenal and Astugenal) to standard radiation therapy helps people aged 3 and older with a newly diagnosed, aggressive brainstem tumor live longer. About 92 participants will be randomly assigned to get either radiation alone or radiation plus the drug combo. The main goal is to see if the combination improves overall survival and to check for side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Antineoplastons A10 (Atengenal) and AS2-1 (Astugenal)
What this could lead to: If it works, this could point toward a treatment that extends survival for children and young adults with a rare and aggressive brainstem tumor.
What could go wrong: This is an early-stage Phase 3 trial with only 92 participants, so results may not be conclusive. Antineoplastons are controversial and not widely accepted, so the treatment may not prove effective or safe.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BRAIN STEM GLIOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

brain stem glioma diffuse intrinsic pontine glioma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BRAIN STEM GLIOMA

More trials for these conditions

Other studies related to the condition(s) this trial covers.